Loading…
Attending this event?

Sign up or log in to bookmark your favorites and sync them to your phone or calendar.

Tuesday, March 10
 

8:00am

9:00am

Chairperson’s Opening Remarks
Tuesday March 10, 2020 9:00am - 9:15am

9:15am

Establish an Integrated and Optimized BD&L Process
  • Identify strategies to get the most out of your team during the entire BD&L process
  • Outline how to systemize the search and evaluation, diligence, contracting process
  • Discuss when specific team members get involved while the roles of others taper down
  • Define the roles, responsibilities, and efforts of each function at various parts of the life cycle

Speakers
JK

John Krayacich

Senior Vice President and Head, Global Business Development, LEO PHARMA


Tuesday March 10, 2020 9:15am - 10:00am

10:00am

Partner to Unlock the Value of Platform Technologies
  • Understand any special considerations for platform technologies from the legal and business development perspective
  • Discuss whether it’s more beneficial to consider the long-term potential for these delivery mechanisms and avoid having to renegotiate down the road or focus on one particular scenario to not skew the forecast
  • Hear how to utilize partnerships to maximize the value of a platform and spread your bets beyond what a single company can achieve

Speakers
avatar for Karah Parschauer

Karah Parschauer

EVP, General Counsel, ULTRAGENYX
avatar for David Slack, MBA

David Slack, MBA

Chief Business Officer, VIRACTA THERAPEUTICS
David has a track record of innovation in business development, fundraising and in senior management positions at public and private biotech as well as large pharmaceutical companies. His deal-making experience encompasses well over $1 billion in corporate partnerships, spin-outs... Read More →


Tuesday March 10, 2020 10:00am - 10:45am

10:45am

Networking Break
Tuesday March 10, 2020 10:45am - 11:15am

11:15am

Compare and Contrast Different Operating Models for Search and Evaluation to Advance Innovation
  • Analyze new growth opportunities and how they should align favorably with your company’s growth culture and objectives
  • Discuss the various formal processes, metrics, and models for prioritization
  • Understand the broader goals of your business development strategy, such as geographic expansion, market share increases, and accelerated top-line growth
  • Weigh the pros and cons of R&D and innovation hubs as a way to partner with existing ecosystems

Speakers
avatar for Christopher Haskell, Ph.D.

Christopher Haskell, Ph.D.

Vice President, Head Open Innovation Center — North America West, BAYER
Dr. Chris Haskell leads Bayer’s West Coast Innovation Center, located in the Mission Bay neighborhood of San Francisco, Calif. The West Coast Innovation Center supports Bayer’s Drug Discovery activities by developing and managing partnerships with U.S. academic research institutions... Read More →
avatar for Jennifer Leeds, Ph.D.

Jennifer Leeds, Ph.D.

Executive Director, BD&L, NOVARTIS


Tuesday March 10, 2020 11:15am - 12:00pm

12:00pm

Navigate BD Deals Involving Digital Health Targets
  • Consider the various product categories that can fall under the “digital health” definition
  • Understand the impact technology can have on the effectiveness of your operations and product portfolio
  • Analyze different valuation approaches and how it can be difficult to monetize or attribute a value to the benefits of digital health assets
  • Consider key questions to ask during the diligence process

Speakers
avatar for Antoun Nabhan, J.D.

Antoun Nabhan, J.D.

Vice President, Corporate Development, PEAR THERAPEUTICS
Antoun has experience leading the corporate development and/or finance functions at several successful biotechnology and medical device companies.Antoun Nabhan was Vice President of Corporate Development at Raptor Pharmaceuticals, Inc., where he oversaw licensing and strategic transactions... Read More →


Tuesday March 10, 2020 12:00pm - 12:45pm

12:45pm

Luncheon
Tuesday March 10, 2020 12:45pm - 1:45pm

1:45pm

Track Chair Opening Remarks
Tuesday March 10, 2020 1:45pm - 2:00pm

1:45pm

Track Chair Opening Remarks
Tuesday March 10, 2020 1:45pm - 2:00pm

2:00pm

Maintain Asset Value for Out-Licensing When a Deprioritized Portfolio No Longer Fits Your Corporate Strategy
  • Consider the strategic reasons and rationale for out-licensing an asset
  • Outline some important things to consider with respect to logistics, legal, and assembling a BD team when you don’t have internal resources
  • Understand what the criteria are for selecting an out-licensing partner

Speakers
avatar for Jennifer Leeds, Ph.D.

Jennifer Leeds, Ph.D.

Executive Director, BD&L, NOVARTIS


Tuesday March 10, 2020 2:00pm - 2:45pm

2:00pm

Get the Most Out of Your IP Due Diligence
  • Understand what your IP team needs in order to conduct efficient diligence
  • Consider the types of IP issues that arise in diligence and how they can derail or delay a deal
  • Discuss tips for structuring IP terms to reflect issues found in diligence

Tuesday March 10, 2020 2:00pm - 2:45pm

2:45pm

Weigh Key Criteria in a Partnership — How to Decide When the “Perfect” Partner and Deal Don’t Exist
  • Consider a potential partner’s reputation and expertise
  • Evaluate the R&D champion – will their tenure outlast the collaboration?
  • Assess whether your goals fit with a partner’s R&D strategy
  • Discuss the importance of greater control versus economic incentives when considering a deal

Speakers
avatar for Philip Gutry

Philip Gutry

Chief Business Officer, KRONOS BIO


Tuesday March 10, 2020 2:45pm - 3:30pm

2:45pm

The Impact of IP in Mergers
  • Understand how early you can anticipate a merger
  • Outline various directions for how a filing can be structured
  • Discuss how to work with BD to conduct IP due diligence and what to do once you have the findings

Speakers
avatar for Olga Kay, J.D., Ph.D.

Olga Kay, J.D., Ph.D.

Senior IP Counsel, ROCHE MOLECULAR SOLUTIONS


Tuesday March 10, 2020 2:45pm - 3:30pm

3:30pm

Networking Break
Tuesday March 10, 2020 3:30pm - 4:00pm

4:00pm

The Role of Preclinical and Clinical Quality in Business Development Opportunities
  • Determine whether preclinical and clinical work for approved/pending products has been conducted within quality standards
  • Evaluate data utilized for Investigational New Drug (IND) or other HA applications
  • Review data storage and transfer practices, as well as pivotal tests for data traceability, integrity, and potential bias
  • Determine GLP/GCP regulation compliance, HA history
  • Evaluate the target company SOPs, processes, quality culture and assess vendor selection and management

If you are interested in leading this session, please contact Michael Williams at mwilliams@exlevents.com.

Tuesday March 10, 2020 4:00pm - 4:45pm

4:00pm

Successfully Navigate Antitrust Aspects of Future Transactions
  • Gain an overview of recent U.S. and global antitrust enforcement trends
  • Discuss key tactics to manage the expectations of your partners
  • Develop an efficient process to assess antitrust risks while increasing the speed of clearance reviews

Tuesday March 10, 2020 4:00pm - 4:45pm
 
Wednesday, March 11
 

8:00am

Continental Breakfast
Wednesday March 11, 2020 8:00am - 9:00am

9:00am

Recap of Day One
Wednesday March 11, 2020 9:00am - 9:15am

9:00am

Recap of Day One
Wednesday March 11, 2020 9:00am - 9:15am

9:15am

Chorus: A Model to Externally Fund the Development of Deprioritized Assets From R&D to PoC
  • Examine how Chorus, an autonomous R&D unit within Eli Lilly, functions as a lean approach to develop, de-risk and increase the value of early phase assets
  • Explore how this model aligns with Lilly’s capital fund strategy and works with outside venture capital to continue programs outside of Lilly’s core focus areas
  • Hear case examples and success stories since Chorus’ inception

Speakers
avatar for Linus S Lin, Ph.D.

Linus S Lin, Ph.D.

Managing Director, Chorus, ELI LILLY


Wednesday March 11, 2020 9:15am - 10:00am

9:15am

Key Considerations for M&A and Asset Purchases From a Private Company
  • Establish what the deductible will be and how the liability works
  • Gain an understanding of their compliance history and how things can go south in a deal
  • Outline best practices for protecting your organization as an acquirer of rights and ensuring last year’s taxes are clean

Wednesday March 11, 2020 9:15am - 10:00am

9:45am

Uncertainty, Challenges, and Implications of Today’s Reimbursement Environment on the Deal-Making Landscape
  • Consider the rising importance of a product’s commercial versus clinical success when evaluating a potential target
  • Discuss the impact of payer consolidation and the evolving healthcare landscape
  • Explore how pricing practices have drawn public and government scrutiny and how this close examination has impacted deal structuring

Speakers
avatar for Sheldon L Koenig, MBA

Sheldon L Koenig, MBA

Executive Vice President and Chief Commercial Officer, PORTOLA PHARMACEUTICALS


Wednesday March 11, 2020 9:45am - 10:30am

9:45am

Strategic Considerations When Preparing for an IPO
  • Discuss the situational drivers and motivations for a company to pursue an IPO
  • Understand the challenges of transitioning from a private to public enterprise and the process and cultural transformation required
  • Outline an IPO readiness assessment checklist that can help avoid common challenges
  • Determine the best timing for your organization to go public

Wednesday March 11, 2020 9:45am - 10:30am

10:30am

Networking Break
Wednesday March 11, 2020 10:30am - 11:00am

11:00am

Partner With Academic Institutions on Early Stage Assets
  • Understand the unique challenges and considerations for negotiating an academic license with respect to IP and publication rights
  • Discuss how technology transfer offices are often balancing the competing interests of various stakeholders within an academic institution and how this can create a conflict of interest
  • Examine the trend of university spin-offs raising considerably high Series A funding and how that factors into your value proposition

Wednesday March 11, 2020 11:00am - 11:45am

11:00am

Explore Innovative Deal Constructs and Risk-Sharing Structures for Licensing and Acquisition Deals
  • Review the risks and hurdles to watch out for from an accounting point of view
  • Evaluate how robust your governance structure should be before you start to control the development of an options-based asset
  • Discuss the best ways to structure options agreements and how to minimize exposure to your P&L while ensuring the requisite controls needed

Speakers
avatar for Jay Parrish

Jay Parrish

Chief Business Officer, VIR BIOTECHNOLOGY
avatar for Neil Abdollahian, M.S., M.B.A.

Neil Abdollahian, M.S., M.B.A.

Chief Business Officer, CIDARA THERAPEUTICS
Mr. Abdollahian has over 16 years of corporate strategy, partnering and M&A experience in the biopharmaceutical industry and leads Cidara’s business development strategy and execution. Prior to joining Cidara, Mr. Abdollahian was Managing Director of Clarity Point Partners, a strategic... Read More →


Wednesday March 11, 2020 11:00am - 11:45am

11:45am

Luncheon
Wednesday March 11, 2020 11:45am - 12:45pm

12:45pm

How to Successfully Operate a Company Built for Acquisition
  • Discuss how to balance making investors happy with running a company
  • Analyze approaches for attracting key talent that buy into the corporate strategy
  • Discuss how to gain internal alignment around a strategy based on your core business and how to make the case to build a commercial organization versus finding a large pharma partner

Wednesday March 11, 2020 12:45pm - 1:30pm

1:30pm

Corporate Venture Funds — Strategic Partners or Not?
  • Assess the rationale and motivations for building a corporate venture arm
  • Learn how the corporate venture funds operate within the constructs of big pharma that are not typically designed for these sort of investments
  • Consider the benefits of working as a strategic partner with your BD colleagues
  • Discuss how you manage competition with external VCs as well as internal BD groups

Wednesday March 11, 2020 1:30pm - 2:15pm

2:15pm

Chairperson’s Closing Remarks
Wednesday March 11, 2020 2:15pm - 2:30pm

2:30pm

Conference Concludes
Wednesday March 11, 2020 2:30pm - 2:30pm